BPMC Stock Summary and Trading Ideas (Blueprint Medicines | NASDAQ:BPMC)

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Blueprint Medicines trades on the NASDAQ stock market under the symbol BPMC.

As of April 18, 2024, BPMC stock price climbed to $88.90 with 708,159 million shares trading.

BPMC has a beta of 1.07, meaning it tends to be more sensitive to market movements. BPMC has a correlation of 0.06 to the broad based SPY ETF.

BPMC has a market cap of $5.44 billion. This is considered a Mid Cap stock.

Last quarter Blueprint Medicines reported $72 million in Revenue and -$1.82 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.22.

In the last 3 years, BPMC stock traded as high as $117.86 and as low as $37.82.

The top ETF exchange traded funds that BPMC belongs to (by Net Assets): VTI, VB, IWM, VXF, VBK.

BPMC has outperformed the market in the last year with a price return of +84.2% while the SPY ETF gained +22.3%. BPMC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +12.0% and -3.6%, respectively, while the SPY returned +6.1% and -3.8%, respectively.

BPMC support price is $85.48 and resistance is $91.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BPMC stock will trade within this expected range on the day.